AI Article Synopsis
Article Abstract
De-escalation of axillary surgery is made possible by advancements in both neoadjuvant systemic therapy (NST) and in localisation technology for breast lesions. Magseed, developed in 2013 by Dr. Michael Douk of Cambridge, United Kingdom, is a wire-free localisation technology that facilitates the localisation and retrieval of lymph nodes for staging. Targeted axillary dissection (TAD), which entails marked lymph node biopsy (MLNB) and sentinel lymph node biopsy (SLNB), has emerged as the preferred method to assess residual disease in post-NST node-positive patients. This systematic review and pooled analysis evaluate the performance of Magseed in TAD. The search was carried out in PubMed and Google Scholar. An assessment of localisation, retrieval rates, concordance between MLNB and SLNB, and pathological complete response (pCR) in clinically node-positive patients post NST was undertaken. : Nine studies spanning 494 patients and 497 procedures were identified, with a 100% successful deployment rate, a 94.2% (468/497) [95% confidence interval (CI), 93.7-94.7] localisation rate, a 98.8% (491/497) retrieval rate, and a 68.8% (247/359) [95% CI 65.6-72.0] concordance rate. pCR was observed in 47.9% (220/459) ) [95% CI 43.3-52.6] of cases. Subgroup analysis of studies reporting the pathological status of MLNB and SLNB separately revealed an FNR of 4.2% for MLNB and 17.6% for SLNB ( = 0.0013). Mean duration of implantation was 37 days (range: 0-188). These findings highlight magnetic seed localisation's efficacy in TAD for NST-treated node-positive patients, aiding in accurate axillary pCR identification and safe de-escalation of axillary surgery in excellent responders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11122577 | PMC |
| http://dx.doi.org/10.3390/jcm13102908 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adjuvant Therapy after Esophagectomy for Esophageal Cancer: Who Needs It?: Multi-institution Worldwide Observational Study.
Ann Surg Open
December 2024
Division of Biostatistics, Department of Public Health Sciences, University of Miami, Miami, FL.
Objective: Based on current practice guidelines, we hypothesized that most patients with esophageal cancer, particularly those with locally advanced cancer, would benefit from adjuvant therapy after esophagectomy esophagectomy alone. We sought to obtain a granular estimate of patient-level risk-adjusted survival for each therapeutic option by cancer histopathology and stage.
Background: Although esophagectomy alone is now an uncommon therapy for treating locally advanced esophageal cancer, the value of adjuvant therapy after esophagectomy is unknown.
Low Levels of High-Density Lipoprotein are Associated With Poor Prognosis in Patients With Early Triple-Negative Breast Cancer.
Cancer Control
December 2024
Department of Surgical Oncology, Zhejiang University Medical School Affiliated Sir Run Run Shaw Hospital, Hangzhou, China.
Background: Although dyslipidemia has been shown to be associated with breast cancer prognosis, the prognostic value of high-density lipoprotein (HDL) in triple-negative breast cancer (TNBC) remains uncertain. The purpose of this study was to evaluate the relationship between preoperative HDL levels and prognosis in TNBC patients.
Methods: Preoperative HDL levels and clinical data from 287 patients who underwent TNBC surgery were retrospectively collected.
[Clinical Study of Lymph Node Dissection in Robot-Assisted Radical Prostatectomy for High-Risk Prostate Cancer].
Hinyokika Kiyo
November 2024
The Department of Urology, Kyoto University Hospital.
We retrospectively analyzed the regions and perioperative outcomes associated with lymph node dissection in patients with prostate cancer. Of 543 patients who underwent robot-assisted radical prostatectomy for prostate cancer with or without lymph node dissection according to the modified D'Amico criteria, 333 (61.3%), 128 (23.
View Article and Find Full Text PDFPatterns of Failure After Definitive Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer
October 2024
Division of Hematology-Oncology, Department of Medicine, University of California San Diego. La Jolla, CA. Electronic address:
Background: Real-world outcomes, especially patterns of failure, are limited for patients with muscle-invasive bladder cancer (MIBC) treated with trimodality therapy (TMT). We aim to evaluate patterns of failure after TMT for MIBC in a typical heterogeneous population.
Methods: In the national Veterans Affairs database, patients with urothelial histology, MIBC (T2-4a/N0-3/M0) who underwent definitive intent TMT between 2000-2018.
Can knowledge-based planning models validated on ethnically diverse patients lead to global standardisation of external beam radiation therapy for locally advanced cervix cancer?
Radiother Oncol
December 2024
Department of Radiation Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Kharghar, Navi Mumbai, Maharashtra, India. Electronic address:
Background And Purpose: Knowledge-based planning (KBP) can consistently and efficiently create high-quality Volumetric Arc Therapy (VMAT) plans for cervix cancer. This study describes the cross-validation of two KBP models on geographically distinct populations and their comparison to manual plans from 67 centers. The purpose was to determine the universal applicability of a generic KBP model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!